Response gene to complement 32 promotes tumorigenesis by mediating DNA damage repair and inhibits CD8+ T cells infiltration in diffuse large B-cell lymphoma
This study highlights that RGC32 is a novel molecule in DLBCL progression and might be a potential therapeutic target for DLBCL therapy.
Authors
- Chunlei Shi (ORCID: https://orcid.org/0000-0002-5847-7122)
- Xin Wang (ORCID: https://orcid.org/0000-0001-8051-1481)
- Ling Wang (ORCID: https://orcid.org/0000-0003-1736-7880)
- Xiyuan Zhang (ORCID: https://orcid.org/0000-0001-9949-5258)
- Mengfei Ding
- Xinting Hu
- Tiange Lu
Institutions
- Qingdao University (CN)
- Shandong Provincial Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1591615
- Citations
- 2
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Shandong First Medical University
- Key Technology Research and Development Program of Shandong